Hogan Lovells advised Mind Medicine Inc. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), completed its underwritten public offering of 9,285,511 common shares, without value, at an offering...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Mind Medicine on the deal. Clinical stage biopharmaceutical company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), completed its underwritten offering of 16,666,667 common shares,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises MindMed in growth financing with K2 HealthVentures. Mind Medicine Inc. (MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Cooley represent MindMed in connection with the proxy contest. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) has announced its successful proxy...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt LLP acted as Canadian counsel to MindMed on the matter. On May 16, 2022, Mind Medicine (MindMed) announced it had implemented a US$100 million...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce LLP acted for MindMed in its Nasdaq up-listing Mind Medicine (MindMed) Inc. has completed its up-listing to The Nasdaq Capital Market, where its subordinate voting...
You must be a Standard 1 Year member to access this content.
Cassels acted for MindMed on the operation. On April 9, 2021, Mind Medicine (MindMed) Inc. filed a short form base shelf prospectus with securities regulators in...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce LLP acted for MindMed. Mind Medicine (MindMed) Inc. completed a bought deal private placement offering of 6,000,000 units for aggregate gross proceeds of $19,500,000. The...
You must be a Standard 1 Year member to access this content.
